2,4,6-Trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer

摘要

Compounds having formula I are provided where the variables have the values described herein. (I). Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and apharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.